BACE1 and Alzheimer disease: Among the resultinganalogs, compound 208 (Table ), bearing a fluoromethyl group, demonstratedpotent BACE-1 inhibition, robust CNS exposure, significant Aβ-loweringeffects in both rodent and canine models, and evidence of amyloidplaque reduction in Alzheimer’s disease mouse models.